Five Signals Your Health Tech Pipeline Is Not Real

Boards ask for a forecast. Teams produce one. Then the quarter closes at a fraction of it, and nobody can say which assumption broke. These five signals show up before the miss.

1. Every opportunity has one contact

Health system purchases involve a clinical champion, an economic buyer, and a reviewing committee at minimum. A single-threaded deal is a relationship, not an opportunity. Fix: no deal advances past early stage without a named economic buyer.

2. Stages describe your activity, not the buyer

Stages named after what your team did, such as demo sent or proposal delivered, measure effort. Stages named after buyer commitments, such as evaluation approved or budget confirmed, measure progress. Rename them and half the pipeline will visibly drop back a stage, which is the point.

3. Nothing ever dies

A pipeline where deals never close-lose is a pipeline being used to reassure people. Set an inactivity rule and enforce it. A smaller honest number is more useful than a large fictional one.

4. Close dates cluster at quarter end

If most close dates sit on the last week of the quarter, they were set by internal wishes rather than the buyer calendar. Date deals from the buyer committee schedule and the capital cycle instead.

5. No one can name the objection that kills deals

Every category has one dominant blocker, whether reimbursement uncertainty, integration burden, or incumbent contract lock-in. A team that cannot name it has not lost enough deals consciously. Fix: run a loss review on the last ten and count causes.

None of these fixes require new headcount. They require the discipline to let the pipeline show its real size, which is the only starting point for growing it.